GOG-3101 | TroFuse-20 Clinical Trial Update

In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer.

★ Support this podcast ★

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(19)

GOG-3073/ ENGOT-ov72/ APGOT-Ov10/ LACOG-0223/ ROSELLA FDA APPROVAL PODCAST

10 Juli 9min

InnovaTV 205 GOG-3024/ENGOT-cx8 Publication Podcast

26 Juni 11min

Uterine Cancer Awareness Month 2026 Podcast

26 Juni 7min

Accrual Culture: Top Points for Site Selection - Timelines

The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG GYN-LIVE Podcast:Corcept Therapeutics, GSK, Pfizer Oncology, Eli Lilly, Genmab, and Verastem ★ Su...

2 Apr 20min

Accrual Culture: Top Points for Site Selection - Responsiveness

6 Mars 17min

The GOG Highlight Reel - January 2026

The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major me...

20 Feb 2h 15min